27406 Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6–11 years with and without comorbid asthma

Abstract

Background: Atopic dermatitis (AD), a chronic inflammatory skin disease, frequently occurs with atopic comorbidities, including asthma. Dupilumab inhibits interleukin-4 and interleukin-13 signaling and is approved for treating multiple type 2 inflammatory diseases, including AD and asthma. Here, we evaluate the efficacy of dupilumab with concomitant topical corticosteroids (TCS) in severe AD in children with and without comorbid asthma.